To assess the application of our prediction model in ex vivo settings, we utilized a publicly available scRNAseq dataset of GBM acute slice cultures treated with the pan-HDAC inhibitor panobinostat (Zhao et al., 2019) (Supplementary Fig. 8a, b)51. This evidence concerns the gene HDAC9 and glioblastoma.